Regulatory De-Risking and Priority Review for Hydronidone Underscore Upside in Gyre Therapeutics Shares
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Matthew Keller has reiterated a Buy rating on Gyre Therapeutics, setting a price target of $18.00. He cites improved outlook due to regulatory clarity from China's Center for Drug Evaluation regarding hydronidone for chronic hepatitis B-related liver fibrosis. The drug qualifies for Priority Review, indicating medical need and innovation. Keller sees a defined timeline for a New Drug Application in 2026, reducing development risks. He believes the positive stock reaction reflects market recognition of this de-risking and the potential value of hydronidone, supporting his Buy recommendation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments